2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Luciano J. Costa, MD, PhD, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study in relapsed/refractory multiple myeloma.
Luciano J. Costa, MD, PhD, an associate professor of medicine in the Blood and Marrow Transplantation and Cell Therapy Program of the University of Alabama's Birmingham School of Medicine, sheds light on CC-93269, a BCMA 2+1 T-cell engager, under examination in a phase 1 dose-finding study (NCT03486067) in relapsed/refractory multiple myeloma.
In the study, investigators assessed the safety and tolerability, as well as the maximum tolerated dose of CC-93269 in patients with relapsed/refractory multiple myeloma. CC-93269 is a 2+1 IgG1-based T cell engager that has 2 binding domains for BCMA, which is universally expressed on myeloma cells, and has one lower affinity domain for CD3, says Costa. By having this configuration, with more binding sites to BCMA and weaker binding sites to CD3, the agent has a much longer half-life, says Costa.
The agent also has a more specific binding to BCMA, preventing nonspecific binding and minimizing the off-target inflammatory toxicity, concludes Costa.